t was only two weeks ago that we wrote a bullish review of Bristol-Myers Squibb (BMY - Get Report) , and it has continued to move higher. I liked BMY on Aug. 31 and said, “I like the charts and indicators right now on BMY and I would be a buyer here risking a close below $54. On the upside, I would set my sights on the $69-$72 area.”
